385 related articles for article (PubMed ID: 19874086)
1. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
[TBL] [Abstract][Full Text] [Related]
2. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
3. Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1.
Kamiya N; Kaartinen VM; Mishina Y
Biochem Biophys Res Commun; 2011 Oct; 414(2):326-30. PubMed ID: 21945937
[TBL] [Abstract][Full Text] [Related]
4. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Modulates Bone Morphogenetic Protein-Induced Sclerostin Expression Through the Wnt Signaling Pathway.
Kim RY; Yang HJ; Song YM; Kim IS; Hwang SJ
Tissue Eng Part A; 2015 Jul; 21(13-14):2076-88. PubMed ID: 25837159
[TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
7. The role of BMPs in bone anabolism and their potential targets SOST and DKK1.
Kamiya N
Curr Mol Pharmacol; 2012 Jun; 5(2):153-63. PubMed ID: 21787290
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.
Winkler DG; Sutherland MS; Ojala E; Turcott E; Geoghegan JC; Shpektor D; Skonier JE; Yu C; Latham JA
J Biol Chem; 2005 Jan; 280(4):2498-502. PubMed ID: 15545262
[TBL] [Abstract][Full Text] [Related]
9. Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass.
Kamiya N; Ye L; Kobayashi T; Lucas DJ; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
J Bone Miner Res; 2008 Dec; 23(12):2007-17. PubMed ID: 18684091
[TBL] [Abstract][Full Text] [Related]
10. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
11. Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation.
Hie M; Iitsuka N; Otsuka T; Tsukamoto I
Int J Mol Med; 2011 Sep; 28(3):455-62. PubMed ID: 21567076
[TBL] [Abstract][Full Text] [Related]
12. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of GSK3β Stimulates BMP Signaling and Decreases SOST Expression Which Results in Enhanced Osteoblast Differentiation.
Schoeman MA; Moester MJ; Oostlander AE; Kaijzel EL; Valstar ER; Nelissen RG; Löwik CW; de Rooij KE
J Cell Biochem; 2015 Dec; 116(12):2938-46. PubMed ID: 26095393
[TBL] [Abstract][Full Text] [Related]
14. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop.
Rawadi G; Vayssière B; Dunn F; Baron R; Roman-Roman S
J Bone Miner Res; 2003 Oct; 18(10):1842-53. PubMed ID: 14584895
[TBL] [Abstract][Full Text] [Related]
15. SOST Inhibits Prostate Cancer Invasion.
Hudson BD; Hum NR; Thomas CB; Kohlgruber A; Sebastian A; Collette NM; Coleman MA; Christiansen BA; Loots GG
PLoS One; 2015; 10(11):e0142058. PubMed ID: 26545120
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
Dai J; Hall CL; Escara-Wilke J; Mizokami A; Keller JM; Keller ET
Cancer Res; 2008 Jul; 68(14):5785-94. PubMed ID: 18632632
[TBL] [Abstract][Full Text] [Related]
17. Controversy of physiological vs. pharmacological effects of BMP signaling: Constitutive activation of BMP type IA receptor-dependent signaling in osteoblast lineage enhances bone formation and resorption, not affecting net bone mass.
Kamiya N; Atsawasuwan P; Joiner DM; Waldorff EI; Goldstein S; Yamauchi M; Mishina Y
Bone; 2020 Sep; 138():115513. PubMed ID: 32603910
[TBL] [Abstract][Full Text] [Related]
18. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF.
Fujita K; Janz S
Mol Cancer; 2007 Oct; 6():71. PubMed ID: 17971207
[TBL] [Abstract][Full Text] [Related]
20. Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts.
Zhang R; Oyajobi BO; Harris SE; Chen D; Tsao C; Deng HW; Zhao M
Bone; 2013 Jan; 52(1):145-56. PubMed ID: 23032104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
